GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: DA-1241 | DA1241
Compound class:
Synthetic organic
Comment: Vanoglipel is the INN for a GPR119 agonist. It is proposed as a therapeutic for use in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes [2-3]. The chemical structure is a match for DA-1241 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Kim MK, Cheong YH, Lee SH, Kim TH, Jung IH, Chae Y, Lee JH, Yang EK, Park H, Yang JS et al.. (2021)
A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression. Biomed Pharmacother, 144: 112324. [PMID:34678732] |
|
2. Lee SH, Park H, Yang EK, Lee BR, Jung IH, Kim TH, Goo MJ, Chae Y, Kim MK. (2023)
GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling. Biomed Pharmacother, 166: 115345. [PMID:37657264] |
|
3. Yoo J, Jun JE, Jeong IK, Ahn KJ, Chung HY, Lee MS, Hwang YC. (2025)
DA-1241, a GPR119 Agonist, Ameliorates Fatty Liver Through the Upregulation of TFEB-Mediated Autophagy. Diabetes, 74 (7): 1107-1120. [PMID:40153257] |